Jubilant Pharmova's Long-Term Growth Outpaces Market Despite Recent Fluctuations

Jubilant Pharmova, a mid-cap player in the Pharmaceuticals & Drugs industry, has shown notable activity in the stock market today. With a market capitalization of Rs 14,941.00 crore, the company has a price-to-earnings (P/E) ratio of 33.00, which is slightly below the industry average of 35.87.
Over the past year, Jubilant Pharmova has outperformed the Sensex, delivering a remarkable 54.38% return compared to the Sensex's modest 0.29%. However, the stock has faced some challenges recently, with a slight decline of 0.19% today, while the Sensex dipped by just 0.01%. In the short term, the stock has gained 0.44% over the past week, although it has experienced a more significant drop of 8.70% over the past month.

Longer-term performance metrics reveal a strong upward trajectory, with a 129.67% increase over the past three years and a 90.17% rise over five years. Despite recent fluctuations, Jubilant Pharmova's decade-long performance stands out, boasting an impressive 488.76% increase, significantly outpacing the Sensex's 152.41% growth during the same period.